Tsc1 expression by dendritic cells is required to preserve T-cell homeostasis and response

Cell Death and Disease

Volumn 8, Issue 1, 2017, Pages

  Luo, Yuechen ^a   Li, Wenwen ^a   Yu, Gang ^b,c   Yu, Juan ^d   Han, Ling ^a   Xue, Ting ^d   Sun, Zhina ^a   Chen, Song ^a   Fang, Chunming ^a   Zhao, Chunxiao ^a   Niu, Qing ^a   Yang, Fei ^a   Han, Zhongchao ^a   Cheng, Tao ^a   Zeng, Yun ^e   Liao, Fang ^d   Xu, Guogang ^b,c   Feng, Xiaoming ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c NANCHANG UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BIM PROTEIN; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; L SELECTIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPILIN 1; OX40 LIGAND; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN KINASE B; RAPTOR PROTEIN; REACTIVE OXYGEN METABOLITE; S6 KINASE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOXP3; TUBEROUS SCLEROSIS 1; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, MOUSE; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTIGEN TRANSPORTATION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; GENE REPRESSION; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; HOMEOSTASIS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 85030986816     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.487     Document Type: Article

References (38)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31: 563-604.
3. Ohnmacht C, Pullner A, King SB, Drexler I, Meier S, Brocker T et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009; 206: 549-559.
4. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000; 191: 927-936.
5. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-667.
6. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol 2012; 30: 39-68.
7. Yang K, Chi H. Tuning mTOR activity for immune balance. J Clin Invest 2013; 123: 5001-5004.
8. Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol 2015; 15: 599-614.
9. Sathaliyawala T, O'Gorman WE, Greter M, Bogunovic M, Konjufca V, Hou ZE et al. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 2010; 33: 597-606.
10. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-4463.
11. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-577.
12. Ohtani M, Nagai S, Kondo S, Mizuno S, Nakamura K, Tanabe M et al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 2008; 112: 635-643.
13. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-1087.
14. Pan H, O'Brien TF, Wright G, Yang J, Shin J, Wright KL et al. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J Immunol 2013; 191: 699-707.
15. Wang Y, Huang G, Zeng H, Yang K, Lamb RF, Chi H. Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci USA 2013; 110: E4894-E4903.
16. Mortier E, Advincula R, Kim L, Chmura S, Barrera J, Reizis B et al. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 2009; 31: 811-822.
17. Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002; 3: 477-482.
18. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
19. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010; 3: 65-79.
20. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008; 28: 4104-4115.
21. Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol 2014; 15: 161-167.
22. Munz C. Autophagy beyond intracellular MHC class II antigen presentation. Trends Immunol 2016; 37: 755-763.
23. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010; 465: 942-946.
24. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002; 14: 129-135.
25. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198: 615-621.
26. Chen M, Wang J. Programmed cell death of dendritic cells in immune regulation. Immunol Rev 2010; 236: 11-27.
27. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat Rev Immunol 2013; 13: 349-361.
28. Deng L, Chen M, Tanaka M, Ku Y, Itoh T, Shoji I et al. HCV upregulates Bim through the ROS/JNK signalling pathway, leading to Bax-mediated apoptosis. J Gen Virol 2015; 96: 2670-2683.
29. Joseph SB, Miner KT, Croft M. Augmentation of naive, Th1 and Th2 effector CD4 responses by IL-6, IL-1 and TNF. Eur J Immunol 1998; 28: 277-289.
30. Rodrigues DA, Gomes CM, Costa IM. Tuberous sclerosis complex. An Bras Dermatol 2012; 87: 184-196.
31. Boer K, Crino PB, Gorter JA, Nellist M, Jansen FE, Spliet WG et al. Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol 2010; 20: 704-719.
32. Prabowo AS, Anink JJ, Lammens M, Nellist M, van den Ouweland AM, Adle-Biassette H et al. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol 2013; 23: 45-59.
33. Singh N, Birkenbach M, Caza T, Perl A, Cohen PL. Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol 2013; 19: 134-137.
34. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 2004; 279: 29930-29937.
35. Feng X, Wang H, Takata H, Day TJ, Willen J, Hu H. Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 2011; 12: 544-550.
36. Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004; 21: 289-302.
37. Sumoza-Toledo A, Fleig A, Penner R. TRPM2 channels are not required for acute airway inflammation in OVA-induced severe allergic asthma in mice. J Inflamm (Lond) 2013; 10: 19.
38. Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, Zwirner J et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21: 279-288.